Aquestive Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Aquestive Therapeutics

02/05/2025 13:20

Aquestive Therapeutics Inc AQST.OQ AQST.O is expected to show a rise in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

The Warren New Jersey-based  company is expected to report a 1.5% increase in revenue to $12.231 million from $12.05 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aquestive Therapeutics Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $9.00​, above​ its last closing price of $3.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.13
-0.14
-0.19
Missed
-40
Sep. 30 2024
-0.12
-0.13
-0.13
Met
-2.6
Jun. 30 2024
-0.13
-0.12
-0.03
Beat
75.8​
Mar. 31 2024
-0.08
-0.08
-0.17
Missed
-106.5
​​Dec. 31 2023
-0.08
-0.08
-0.11
Missed
-37.5
Sep. 30 2023
-0.11
-0.11
-0.03
Beat
73.5​
Jun. 30 2023
-0.12
-0.12
-0.10
Beat
15.3
Mar. 31 2023
-0.18
-0.19
-0.12
Beat
36.5

This summary was machine generated May 2 at 12:20 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)